Evidence map›Paper›PMID 39234853›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2024

Investigation of health care use and a possible prodrome before the first attack in NMOSD and MOGAD.

Dalia L Rotstein, Mark S Freedman, Andrea Konig, Liesly Lee, Jin Luo, Colleen Maxwell, Sarah A Morrow, Helen Tremlett, Manav V Vyas, Ruth Ann Marrie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Dalia L RotsteinSt. Michael's Hospital, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-7280-3684
Mark S FreedmanDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Andrea KonigSt. Michael's Hospital, Toronto, ON, Canada.
Liesly LeeSunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Jin LuoInstitute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Colleen MaxwellInstitute for Clinical Evaluative Sciences, Toronto, ON, Canada; School of Pharmacy, University of Waterloo, Waterloo, ON, Canada.
Sarah A MorrowWestern University, London, ON, Canada; University of Calgary, Calgary, AB, Canada.ORCID 0000-0001-7522-6440
Helen TremlettDivision of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-5804-2535
Manav V VyasSt. Michael's Hospital, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.
Ruth Ann MarrieDepartments of Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.ORCID 0000-0002-1855-5595

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProdromal phases are well recognized in many inflammatory and neurodegenerative diseases, including multiple sclerosis. We evaluated the possibility of a prodrome in aquaporin-4 antibody positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) using health administrative data.

methodsWe investigated individuals with AQP4 + NMOSD and MOGAD, confirmed by medical chart review, in Ontario, Canada. Each NMOSD and MOGAD participant was matched 1:5 to general population controls by sex, birth year, immigrant status, and region. Total outpatient visits and hospitalizations were compared in the 5 years preceding the incident attack in multivariable negative binomial models.

resultsWe identified 96 people with AQP4 + NMOSD, matched to 479 controls, and 61 people with MOGAD, matched to 303 controls. In the 5 years preceding the incident attack, health care use was elevated for outpatient visits and hospitalizations for the NMOSD cohort (adjusted rate ratio (aRR): 1.47; 95% confidence interval (CI): 1.25-1.73; aRR: 1.67; 95% CI: 1.19-2.36, respectively) but not for MOGAD. Rate ratios steadily increased in NMOSD for outpatient visits in the 2 years preceding the incident attack.

conclusionOur findings support a prodromal phase preceding clinical onset of AQP4 + NMOSD. Earlier recognition and management of NMOSD patients may be possible.

Indexed as

Aquaporin 4Myelin-Oligodendrocyte GlycoproteinNeuromyelitis OpticaProdromal SymptomsAdultAutoantibodiesDemyelinating Autoimmune Diseases, CNSFemaleHospitalizationHumansMaleMiddle AgedOntarioPatient Acceptance of Health CareAQP4 protein, humanAquaporin 4AutoantibodiesMyelin-Oligodendrocyte GlycoproteinAQP4MOGADNMOSDprodrome

Identifiers

PMID39234853
PMCPMC11457589

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.